Communiqués TG Therapeutics, Inc. Deutsche Boerse AG

Actions

NKB2

US88322Q1085

Produits pharmaceutiques

Marché Fermé - Deutsche Boerse AG Autres places de cotation 13:20:21 03/08/2026			Varia. 5j.	Varia. 1 janv.
44,70 ^EUR	-2,83%		-7,26%	+74,68%

03/08	TG Therapeutics, Inc. relève ses prévisions de résultats pour l'exercice 2026	CI
03/08	TG Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

03/08	TG Therapeutics : Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance	PU
03/08	TG Therapeutics: Q2 Earnings Snapshot	AQ
03/08	TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance	AQ
29/07	TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update	AQ
06/07	TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia	AQ
09/06	TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial	AQ
03/06	TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)	AQ
02/06	TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference	AQ
01/06	TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology	AQ
28/05	TG Therapeutics to Participate in the Jefferies Global Healthcare Conference	AQ
27/05	TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial	AQ
26/05	TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting	AQ
07/05	TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance	AQ
06/05	TG Therapeutics: Q1 Earnings Snapshot	AQ
06/05	TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance	AQ
30/04	TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update	AQ
22/04	TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting	AQ
15/04	TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI	AQ
19/03	TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million	AQ
09/03	Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis	AQ
06/03	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting	AQ
26/02	TG Therapeutics: Q4 Earnings Snapshot	AQ
26/02	TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance	AQ
23/02	TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update	AQ
17/02	Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis	AQ